2MW 4991
Alternative Names: 2MW-4991Latest Information Update: 15 Jun 2024
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Integrin alphavbeta8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Pharmacokinetics, adverse events and pharmacodynamics data from a preclinical trial in cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 12 Mar 2024 Preclinical trials in Cancer in China (Parenteral) before March 2024
- 12 Mar 2024 Pharmacodynamics data from a preclinical studies in Cancer released by Mabwell (Shanghai) Bioscience